Ceased Operations Lyndra Therapeutics has ceased operations as of March 26, 2025, indicating a need for potential restructuring, asset acquisition opportunities, or collaboration with legacy programs that may align with active biotech portfolios.

Fundraising & M&A Recent financing and acquisition activity shows liquidity events and strategic shifts, with a $101M Series E and a Sun Pharma/ Sun Ophthalmics stake acquisition; opportunities may exist to acquire IP, collaborations, or license agreements around Lyndra’s long-acting oral LAO delivery platforms.

Delivery Platform Lyndra’s focus on cutting-edge delivery technology for long-acting therapies positions potential partners in formulation science, manufacturing scale-up, and regulatory strategy to optimize LAO delivery across CNS, ophthalmology, or opioid use disorder pipelines.

Strategic Partnerships Past collaborations with National Institutes of Health and leadership changes suggest a track record of government and academic partnerships; potential for new joint development programs or funding-aligned projects leveraging existing tech.

Market & Assets With revenues reported in the lower tens of millions and a relatively small team, there may be opportunities to license or acquire select assets, IP, or ongoing programs from Lyndra to accelerate time-to-market for long-acting therapies.